Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 280

1.

Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia.

Pajonk FG, Schreiner A, Peters S, Rettig K, Degner D, Rüther E.

J Clin Psychopharmacol. 2005 Aug;25(4):293-300. Erratum in: J Clin Psychopharmacol. 2006 Feb;26(1):26.

PMID:
16012270
2.

[Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].

Pajonk FG, Schreiner A, Peters S, Rettig K, Degner D, Rüther E.

Fortschr Neurol Psychiatr. 2003 May;71(5):249-54. German.

PMID:
12740756
3.

Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets.

Normann C, Schmauss M, Bakri N, Gerwe M, Schreiner A.

Pharmacopsychiatry. 2006 Nov;39(6):209-12.

PMID:
17124642
4.
5.

Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia.

Lane HY, Chang YC, Cheng YC, Liu GC, Lin XR, Chang WH.

J Clin Psychiatry. 2003 Mar;64(3):316-20.

PMID:
12716274
8.

An open study of risperidone liquid in the acute phase of schizophrenia.

Yoshimura R, Nakamura J, Shinkai K, Goto M, Yamada Y, Kaji K, Kakihara S, Ueda N, Kohara K, Ninomiya H, Egami H, Maeda H.

Hum Psychopharmacol. 2005 Jun;20(4):243-8.

PMID:
15830401
9.

Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility.

Citrome L, Shope CB, Nolan KA, Czobor P, Volavka J.

Int Clin Psychopharmacol. 2007 Nov;22(6):356-62.

PMID:
17917554
10.

Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.

Casey DE, Sands EE, Heisterberg J, Yang HM.

Psychopharmacology (Berl). 2008 Oct;200(3):317-31. doi: 10.1007/s00213-008-1207-7. Epub 2008 Jul 4.

PMID:
18597078
11.

Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.

Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA.

J Clin Psychiatry. 2006 Jul;67(7):1093-103.

PMID:
16889453
12.

Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients.

Möller HJ, Gagiano CA, Addington DE, Von Knorring L, Torres-Plank JF, Gaussares C.

Int Clin Psychopharmacol. 1998 May;13(3):99-106.

PMID:
9690975
13.

Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.

Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R.

Pharmacopsychiatry. 2007 Nov;40(6):257-63.

PMID:
18030649
14.
16.

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.

Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.

Arch Gen Psychiatry. 2005 Nov;62(11):1196-204.

PMID:
16275807
17.

Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels.

Lane HY, Chiu WC, Chou JC, Wu ST, Su MH, Chang WH.

J Clin Psychiatry. 2000 Mar;61(3):209-14.

PMID:
10817107
18.

Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms.

Riedel M, Müller N, Strassnig M, Spellmann I, Engel RR, Musil R, Dehning S, Douhet A, Schwarz MJ, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2005 Dec;255(6):432-7. Epub 2005 Nov 4.

PMID:
16267634
19.

Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants.

Lane HY, Chang YC, Chiu CC, Lee SH, Lin CY, Chang WH.

Psychopharmacology (Berl). 2004 Apr;172(4):393-9. Epub 2003 Dec 9.

PMID:
14663551
20.

Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit R, Engel RR, Kleindienst N, Müller N, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):360-70. Epub 2007 Jul 14.

PMID:
17629731

Supplemental Content

Support Center